DEA keeps classic psychedelics (psilocybin, LSD, DMT) on Schedule I through 2026 with no rescheduling action.

The DEA (the US agency that classifies drugs and enforces drug laws) will keep psilocybin, LSD, and DMT in Schedule I — the strictest category, reserved for substances the government says have no accepted medical use and high abuse potential. The DEA can only reschedule these drugs after the FDA approves one of them as medicine, and that approval isn't happening in 2026. So the federal ban stays in place by default.

Federal rescheduling is statutorily contingent on an FDA approval that is not expected in 2026 (see linked prediction). No rulemaking notice or scheduling petition movement appears in current signals; enforcement posture holds by default.